Evidence map›Paper›PMID 27462507›Full record

ArticleSpringerPlus2016

Doping offences in male professional tennis: how does sanction affect players' career?

Javier Maquirriain, Roberto Baglione

Abstract read
In one paragraph

Article in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Javier MaquirriainHigh Performance National Sports Center, CeNARD, Buenos Aires, Argentina ; Argentine Tennis Association, Chubut 415, Mayling Club de Campo Pilar 1631, Buenos Aires, Argentina ; CONICET, Buenos Aires, Argentina.
Roberto BaglioneHigh Performance National Sports Center, CeNARD, Buenos Aires, Argentina ; Argentine Tennis Association, Chubut 415, Mayling Club de Campo Pilar 1631, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of performance enhancing drugs is still a major problem in competitive sports. Even though tennis is not affected by systematic doping, there is lack of scientific evidence on the effect of sanctions on players` career. The aim of this study was to analyze male tennis players' career after a doping sanction.

methodsAll doping offences committed by male professional tennis players during 2003-2014 were registered from the International Tennis Federation records and analyzed considering three ranking positions: at sanction date, the peak career position, and the highest position after doping violation.

resultsForty-six players (aged 26.04 ± 3.48 years) committed 47 doping offences in a 14-year period with an average ineligibility time of 11.13 ± 9.90 months. Ranking position at sanction date averaged 409.53 ± 437.53 (median 266); the highest career position averaged 201.12 ± 293.96 (median 83) and the highest career position after doping violation was 350.85 ± 441.38 (median 156). Elite players committed less doping offences than players beyond the 100° ranking position (29.78 and 70.21 %, respectively; p < 0.01). Most players (72.34 %) reached their career highest position before the doping sanction (p = 0.01). The average time to retirement was 35.76 ± 31.03 months, while 12 % did not return to professional tennis competition after the doping offence.

conclusionsMost suspended tennis players were not elite players. Doping sanction seems to significantly affect male tennis players' career. Only a minority of sanctioned players could reach their peak ranking position after the doping offence and suspension may accelerate the retirement process.

Indexed as

DrugPerformanceRankingSport

Identifiers

PMID27462507
PMCPMC4942449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.